logo
logo
Sign in

Osimertinib (Osicent 80mg): Understanding Its Role in NSCLC Management

avatar
sasha
Osimertinib (Osicent 80mg): Understanding Its Role in NSCLC Management

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. The management of this disease has evolved significantly in recent years, thanks to the discovery of targeted therapies and advancements in molecular testing. Osimertinib (Osicent 80mg) is one such targeted therapy that has shown impressive results in the treatment of NSCLC, particularly in patients with specific genetic mutations. In this article, we will delve deeper into the mechanism of action of Osimertinib, its role in NSCLC management, and the latest research findings surrounding this promising drug.

What is Osimertinib (Osicent 80mg)?

Osimertinib, sold under the brand name Osicent, is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is used for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed on or after EGFR TKI therapy.

Mechanism of Action

The epidermal growth factor receptor (EGFR) is a protein found on the surface of some cells and plays a critical role in cell growth and division. In certain types of cancer, including NSCLC, the EGFR gene may be mutated, causing the receptor to be overactive and ultimately leading to uncontrolled cell growth. Osimertinib works by selectively inhibiting the activity of the mutated EGFR, thereby blocking the growth and spread of cancer cells.

Role in NSCLC Management

Osimertinib has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic EGFR T790M mutation-positive NSCLC in patients who have progressed on or after first-line EGFR TKI therapy. The drug has demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) when compared to standard chemotherapy in clinical trials.

Moreover, osimertinib has also shown promising results as a first-line treatment for patients with metastatic EGFR-mutated NSCLC. The FLAURA trial, a Phase III clinical trial, demonstrated that osimertinib significantly improved PFS compared to first-generation EGFR TKIs, such as erlotinib and gefitinib. This led to the FDA granting approval for osimertinib as a first-line treatment option in this patient population in 2018.

Latest Research Findings

The role of osimertinib in the treatment of NSCLC continues to expand as more research is conducted. Some of the latest findings include:

1.   Adjuvant therapy: The ADAURA trial demonstrated that osimertinib, when used as adjuvant therapy following complete tumor resection, significantly improved disease-free survival (DFS) in patients with stage IB-IIIA EGFR-mutated NSCLC. These results have prompted discussions on whether osimertinib should be considered a new standard of care for this patient population.

2.   Central nervous system (CNS) metastases: Patients with NSCLC are at a high risk of developing brain metastases. Osimertinib has shown promising activity in the treatment of CNS metastases due to its ability to cross the blood-brain barrier. Several studies have reported high intracranial response rates and improved CNS progression-free survival in patients treated with osimertinib.

Conclusion

Osimertinib (Osicent 80mg) has emerged as a vital targeted therapy in the management


collect
0
avatar
sasha
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more